Marie-Pierre Gourin
A5024987845- Acute Myeloid Leukemia Research
- PARP inhibition in cancer therapy
- Immunodeficiency and Autoimmune Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Mast cells and histamine
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematological disorders and diagnostics
- Pneumocystis jirovecii pneumonia detection and treatment
- Ovarian cancer diagnosis and treatment
- Urticaria and Related Conditions
- Metal complexes synthesis and properties
- Ferrocene Chemistry and Applications
- Histone Deacetylase Inhibitors Research
- Synthetic Organic Chemistry Methods
- Acute Lymphoblastic Leukemia research
- Palliative Care and End-of-Life Issues
- Drug-Induced Adverse Reactions
- Cancer Immunotherapy and Biomarkers
- Otitis Media and Relapsing Polychondritis
- Neutropenia and Cancer Infections
- Brain Metastases and Treatment
- Pediatric health and respiratory diseases
- Ear and Head Tumors
Université de Limoges
2014-2024
Hôpital Dupuytren
2009-2023
Centre Hospitalier Universitaire de Limoges
2010-2022
Limousin Regional Council
2015-2021
Groupe Francophone des Myélodysplasies
2009-2019
Hôpital Avicenne
2009
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed nationwide network to collect data from new cases diagnosed in France. In retrospective, observational study of 86 patients (2000-2013), described clinical biological focusing on morphologies immunophenotype. We found expression markers associated with origin (HLA-DRhigh, CD303+, CD304+, cTCL1+) plus CD4 CD56 frequent isolated the myeloid, B-, T-lymphoid lineages, whereas...
High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is novel subcutaneous hypomethylating agent which results in extended decitabine exposure. This multicenter phase II study evaluated the efficacy and safety of guadecitabine high-risk syndrome low blast count acute refractory or relapsing azacitidine. We included 56 with median age 75 years [Interquartile Range (IQR) 69-76]. Fifty-five received at...
To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi).In a French cancer center, we identified described profiles 13 t-MN diagnosed among 37 patients with ovarian referred to hematology consultation for cytopenia under PARPi. Next, these post-PARPi post according PARPi exposure. Finally, 69 in national cohort.From 2016 2021, cumulative incidence was 3.5% (13/373) treated At time hematologic consultation, had longer...
Although numerous recent publications have demonstrated interest in multiparameter flow cytometry the investigation of myelodysplastic disorders, it is perceived by many laboratory hematologists as difficult and expensive, requiring a high level expertise. We report multicentric open real-life study aimed at evaluating added value technically simple score described Ogata group for diagnosis syndromes. A total 652 patients were recruited prospectively four different centers: 346 syndromes, 53...
Finding new prognostic factors to identify patients with Hodgkin lymphoma (HL) at risk of treatment resistance or relapse remains challenging in daily practice. We evaluated the relationship between CD68 expression, interim positron emission tomography (iPET) results and outcome 158 HL diagnosed from February 1995 July 2011. Immunohistochemistry (anti-CD68) gave two groups: low ≤25% positive cells (121 patients) high >25% (37 patients). Five-year overall survival was higher group (88.4% vs....
During the last few decades, patients' rights have been reinforced in many countries by acts of law. Measures now include health care proxies to uphold doctor-patient relationship and advance directives for end-of-life patients. These could be relevant tools as early initial diagnosis haematological malignancies because uncertain disease course. The aim this research was assess factors associated with designation a proxy writing patients haematology department France. After specific...
Diffuse large B-cell lymphoma (DLBCL) is a fatal malignancy that needs to identify new targets for additional therapeutic options. This study aimed clarify the clinical and biological significance of endogenous neurotrophin (nerve growth factor (NGF) brain-derived neurotrophic (BDNF)) in DLBCL biopsy samples cell lines. We analysed expression NGF, BDNF, their receptors (Trk, p75NTR) 51 biopsies lines by immunohistochemistry, immunofluorescence, western blotting. To investigate role...
Background There is little published information on the everyday clinical management of myelodysplastic syndromes in real world practice.Design and Methods We conducted a cross-sectional study all patients with attending 74 French centers 1-week period for inpatient admission, day-hospital care or outpatient visits.Results Nine hundred seven were included; 67.3% had lower-risk (International Prognostic Scoring System: low intermediate-1). Karyotype been analyzed 82.5% cases was more often...
Relationships between c-Rel and GCB-DLBCLs remain unclear. We found that strong DNA-binding activity was mostly in GCBs on two independent series of 48 DLBCLs 66 DLBCLs, the latter issued from GHEDI series. associated with increased REL mRNA expression. Extending study to whole Lenz DLBCL published 202 233 cases, it gene expression profile (GEP) overlapped partially (12%) but only GCB GEP not ABC-DLBCLs. Cases both overexpression were defined as those having a signature. These cases 88 83%...
Although Hizentra is indicated for immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies, phase III trials have focused on immunodeficiencies. In this 9-month, real-life, prospective, non-interventional, longitudinal, multicenter study of immunodeficiencies France, treatment modalities (primary endpoint), efficacy, safety, tolerability, quality life, satisfaction were evaluated using descriptive statistics.Starting January 2012, 117 enrolled (99 adults,...
The EUROPE phase 2 trial investigated the predictive value of biomarkers on clinical efficacy single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia within 'European Myelodysplastic Neoplasms Cooperative Group' (EMSCO) network. A total 77 LR-MDS a median platelet count 25/nl were included, all received ROM at starting dose 750 μg by SC injection weekly. Thirty-two (42%) achieved hematologic improvement platelets (HI-P)...
Not available.